Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Tyrosine kinase inhibitors
12 evidence topics · 12 sources
NCCN placement of sorafenib, imatinib, and pazopanib as quoted in a payer policy
Guideline updates naming sorafenib a category 1 preferred regimen
“After this analysis ended in August 2023 and the United States Food and Drug Administration (FDA) approval of nirogacestat, the NCCN Guidelines and DTWG guidelines were updated to include sorafenib and nirogacestat as Category 1, Preferred systemic regimens [14, 16, 18].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid Tumor Working Group assessment of tyrosine kinase inhibitors
Sorafenib phase 3 trial: design and efficacy
“In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of the predictable toxic-effects profile and substantial progression-free survival advantage conferred by sorafenib, the drug has antitumor activity as first-line therapy or as subsequent therapy for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sorafenib phase 3 trial: adverse events, dose modification, and discontinuation
“Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruptions occurred in 65% of the patients in the sorafenib group (32 of 49) and 34% of the patients in the placebo group (12 of 35), and dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group. Grade 4 events that were associated with sorafenib included thrombocytopenia (2%) and anemia (2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pazopanib in the DESMOPAZ randomized phase 2 trial
“DESMOPAZ was a non-comparative, randomised, open-label, phase 2 trial conducted at 12 centres from the French Sarcoma Group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomly assigned (2:1) to oral pazopanib 800 mg per day for up to 1 year or to an intravenous regimen combining vinblastine (5 mg/m2 per dose) and methotrexate (30 mg/m2 per dose), administered weekly for 6 months and then every other week for 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the first 43 patients assessable for the primary endpoint in the pazopanib group, the proportion of patients who had not progressed at 6 months was 83·7% (95% CI 69·3-93·2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common grade 3 or 4 adverse events in the pazopanib group were hypertension (n=10, 21%) and diarrhoea (n=7, 15%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“11 patients (23%) had at least one serious adverse event related to study treatment in the pazopanib group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imatinib in the German Interdisciplinary Sarcoma Group phase 2 trial
“We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-eight patients (median age 44 years [range: 19-80]; 68% female; 90% Eastern Cooperative Oncology Group (ECOG) performance status 0) were treated with a daily dose of 800 mg imatinib planned over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The final analysis for the primary end-point in the evaluable patients of the full analysis set revealed a PAR6mo of 65%. Subsequent progression arrest rates at 9, 12, 15, 18, 21 and 24 months were 65%, 59%, 53%, 53%, 50% and 45%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Best reported response was seven partial responses at 21 months revealing an overall response rate of 19%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In general imatinib adverse events were mild to moderate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imatinib in a two-stage phase 2 study
“Forty patients with unresectable and progressive symptomatic AF/DT were treated with imatinib (400 mg/day for 1 year) in a Simon's optimal two-stage phase II study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The non-progression rates at 3, 6 and 12 months were, respectively, 91%, 80% and 67%. The 2-year progression-free and overall survival rates were 55% and 95%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world sorafenib and pazopanib in an 11-institution retrospective cohort
“Patients diagnosed with DTs and treated with sorafenib or pazopanib between 2011 and 2022 at 11 institutions were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“142 patients with DT treated with sorafenib (n = 126, 88.7 %) or pazopanib (n = 16, 11.3 %) were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate and the disease control rate were 26.0 % and 95.1 %, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 1-year and 2-year progression-free survival rates were 82 % and 80 %. Dose reductions were necessary in 34 (23.9 %) patients. Grade 3 or higher adverse events were reported in 36 (25.4 %) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment discontinuation (n = 85, 59.9 %) was mainly for toxicity (n = 35, 45.9 %) or radiological or clinical progression (n = 30, 35.3 %).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sorafenib discontinuation after response in the SORASTOP phase 2 study
“The SORASTOP study reports long-term outcomes following planned sorafenib discontinuation in responding patients with extremity desmoid-type fibromatosis (DTF).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this prospective, single-arm phase 2 Simon's two-stage trial, adults with non-progressive, extremity DTF, ESAS pain < 2, after ≥ 12 months of sorafenib were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PFS at 12, 24 and 36 months were 90.8 %, 74.5 % and 74.5 % respectively; with median follow-up of 37 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tyrosine kinase inhibitor use reported by study participants
“Most participants (76%, 281/369) received systemic therapy (any line), including nonsteroidal anti-inflammatory drugs (NSAIDs; 40%, 112/281), tyrosine kinase inhibitors (32%, 91/281), chemotherapy (31%, 87/281), and hormone antagonists (17%, 47/281; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote